Geneos Wealth Management
RXRX icon

Geneos Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Geneos Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-350
Closed -$1.71K – 2543
2025
Q3 		$1.71K Sell
350
-89
-20% -$467 ﹤0.01% 2340
2025
Q2 		$2.22K Hold
439
– – ﹤0.01% 2788
2025
Q1 		$2.32K Sell
439
-111
-20% -$809 ﹤0.01% 2721
2024
Q4 		$3.72K Buy
550
+200
+57% +$1.34K ﹤0.01% 2436
2024
Q3 		$2.31K Hold
350
– – ﹤0.01% 2265
2024
Q2 		$2.63K Hold
350
– – ﹤0.01% 1839
2024
Q1 		$3.49K Buy
+350
New +$3.9K ﹤0.01% 1785

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geneos Wealth Management's RXRX Position: Q4 2025 in Review

Geneos Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 350 shares — an estimated $1.71K sold.

Geneos Wealth Management first reported a position in RXRX in Q1 2024 and held it in 7 quarters. The position peaked at $3.72K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Geneos Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 350 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.71K.
  • Geneos Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Geneos Wealth Management's Recursion Pharmaceuticals position peaked at $3.72K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Geneos Wealth Management's 13F filing for Q4 2025, filed 28 Jan 2026.